Goldman Sachs’s C4 Therapeutics CCCC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $6.28M | Buy |
2,387,378
+1,298,358
| +119% | +$3.06M | ﹤0.01% | 3477 |
|
|
2025
Q4 | $2.08M | Buy |
1,089,020
+629,127
| +137% | +$1.49M | ﹤0.01% | 4553 |
|
|
2025
Q3 | $1.02M | Sell |
459,893
-420,365
| -48% | -$1.01M | ﹤0.01% | 5001 |
|
|
2025
Q2 | $1.26M | Buy |
880,258
+257,538
| +41% | +$375K | ﹤0.01% | 4525 |
|
|
2025
Q1 | $996K | Buy |
622,720
+49,065
| +9% | +$146K | ﹤0.01% | 4692 |
|
|
2024
Q4 | $2.07M | Buy |
573,655
+67,803
| +13% | +$337K | ﹤0.01% | 4253 |
|
|
2024
Q3 | $2.88M | Sell |
505,852
-231,983
| -31% | -$1.4M | ﹤0.01% | 3827 |
|
|
2024
Q2 | $3.41M | Sell |
737,835
-543,407
| -42% | -$3.24M | ﹤0.01% | 3507 |
|
|
2024
Q1 | $10.5M | Buy |
1,281,242
+1,167,729
| +1,029% | +$9.05M | ﹤0.01% | 2426 |
|
|
2023
Q4 | $641K | Sell |
113,513
-105,210
| -48% | -$240K | ﹤0.01% | 4619 |
|
|
2023
Q3 | $407K | Sell |
218,723
-11,843
| -5% | -$36.1K | ﹤0.01% | 4746 |
|
|
2023
Q2 | $634K | Sell |
230,566
-115,017
| -33% | -$370K | ﹤0.01% | 4612 |
|
|
2023
Q1 | $1.09M | Buy |
345,583
+61,631
| +22% | +$363K | ﹤0.01% | 4329 |
|
|
2022
Q4 | $1.68M | Sell |
283,952
-136,891
| -33% | -$1.14M | ﹤0.01% | 4072 |
|
|
2022
Q3 | $3.69M | Buy |
420,843
+289,119
| +219% | +$3M | ﹤0.01% | 3419 |
|
|
2022
Q2 | $993K | Buy |
131,724
+11,935
| +10% | +$105K | ﹤0.01% | 4608 |
|
|
2022
Q1 | $2.91M | Sell |
119,789
-105,059
| -47% | -$2.55M | ﹤0.01% | 3900 |
|
|
2021
Q4 | $7.24M | Sell |
224,848
-39,116
| -15% | -$1.55M | ﹤0.01% | 3059 |
|
|
2021
Q3 | $11.8M | Buy |
263,964
+33,001
| +14% | +$1.41M | ﹤0.01% | 2561 |
|
|
2021
Q2 | $8.74M | Buy |
+230,963
| New | +$8.27M | ﹤0.01% | 2820 |
|
|
2021
Q1 | – | Sell |
-12,624
| Closed | -$418K | – | 6099 |
|
|
2020
Q4 | $418K | Buy |
+12,624
| New | +$366K | ﹤0.01% | 4710 |
|
Other funds holding CCCC
RCM
BCLSI
LCM
VCM
SCM
WA
